Skip to main content Help with accessibility Skip to main navigation

All Guidance

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - November - 2018
BNF chapter: Central nervous system

Methylphenidate, Lisdexamfetamine, Dexamfetamine, Atomoxetine - For Attention Deficit Hyperactivity Disorder in adults aged over 17 years and in children and adolescents aged 6 to 17 years

Guanfacine - For Attention Deficit Hyperactivity Disorder in children and adolescents aged 6 to 17 years 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 09 - February - 2023
BNF chapter: Endocrine system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 14 - January - 2021
BNF chapter: Cardiovascular system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 16 - June - 2023
BNF chapter: Respiratory system

LSCMMG has granted interim approval for this position statement ONLY. LSCMMG is aware that each locality, prior to the establishment of the ICB, had adopted the 'Over the counter items that should not be routinely prescribed in primary care policy'.

Interim approval has been granted to provide consistency of advice to prescribers whilst the ICB considers whether to adopt the 'Over the counter items that should not be routinely prescribed in primary care policy' across Lancashire and South Cumbria. 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - November - 2014
BNF chapter: Central nervous system

Amisulpride, Aripiprazole, Olanzapine, Quetiapine, Oral Risperidone
This shared prescribing guideline for the second-generation antipsychotic medications listed above has been developed with due consideration to the appropriate NICE Clinical Guidelines (CG) e.g. Bipolar Disorder (CG185), Psychosis and Schizophrenia in Children and Young People (CG155), Psychosis and Schizophrenia in Adults (CG178), Schizophrenia- Aripiprazole (TA213), Bipolar Disorder- Adolescents (TA292).

Please note: Morecambe Bay CCG has now adopted this Shared-care guideline for all areas, including South Cumbria. 

 

Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted
Adopted
Date Posted: 10 - January - 2024
BNF chapter: Central nervous system

Refer to Local Commissioning Policy Before Use

Treatment of Parkinson’s Disease

 

 

Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2018
BNF chapter: Endocrine system
Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2018
BNF chapter: Endocrine system
Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 15 - July - 2020
BNF chapter: Central nervous system
This guideline provides recommendations on the medical management of adults with chronic non-cancer pain.

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 12 - September - 2022
BNF chapter: Respiratory system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 15 - November - 2022
BNF chapter: Respiratory system

This asthma summary guideline has been created in collaboration with the Lancashire and South Cumbria Clinical Asthma Group led by Dr Aashish Vyas, with the aim to provide a consistent approach to asthma treatment for adults within LSCMMG.

BTS/SIGN British Guideline on the Management of Asthma

NICE NG80 - Asthma: diagnosis, monitoring and Chronic Asthma Management

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 19 - February - 2020
BNF chapter: Respiratory system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 24 - October - 2022
BNF chapter: Cardiovascular system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 13 - May - 2022

Radiographic (Ankylosing Spondylitis) and Non-radiographic Axial Spondyloarthritis (ASp) LSCMMG Recommended Biologic Pathway

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted

This guidance does not replace the SPC’s, which should be read in conjunction with this guidance. 

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - June - 2015
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 12 - September - 2019
BNF chapter: Skin

Medical camouflaging products must only be initiated by a healthcare professional that specialises in skin colour matching and appropriate application techniques.
Please note: these products must only be continued in primary care if the patient’s GP believes issuing such a prescription will continue to significantly reduce the impact of the patient’s medical condition.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - January - 2019
BNF chapter: Central nervous system

This guidance does not apply to the use of Sativex® (delta-9-etrahydrocannabinol and cannabidiol) oromucosal spray as an adjunct treatment for moderate to severe spasticity in multiple sclerosis

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 19 - July - 2022
BNF chapter: Central nervous system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted

This guidance does not replace the SPC’s, which should be read in conjunction with this guidance.